Agencies
Services
News Release – Monday, May 1, 2023
Updated IDFPR Statement on Recent Court Rulings About Mifepristone
On Friday, April 21, 2023, the United States Supreme Court stayed the Texas court ruling which had stayed the 2000 FDA approval of Mifepristone pending litigation on the merits. The U.S. Supreme Court ruling means that Mifepristone remains a legal reproductive healthcare option for women in Illinois, as well as across the nation. The Illinois Department of Financial and Professional Regulation (“IDFPR”) will not discipline physicians who prescribe or pharmacists who fulfill prescriptions of Mifepristone.
